<DOC>
	<DOC>NCT00455442</DOC>
	<brief_summary>This is a two-week study testing the efficacy and safety of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers by measuring changes in body weight and BMI.</brief_summary>
	<brief_title>A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Healthy male volunteers between 18 and 40 years of age BMI between ≥ 18 and ≤ 25 Able to provide written informed consent Routine clinical laboratory tests either within normal limits or not clinically meaningful if outside of normal limits History of Cushing's syndrome or Addison's disease Prior or current history of any psychiatric disorder, including eating disorders such as anorexia nervosa, bulimia nervosa, or bingeeating disorder Positive urine drug screen for any nonprescribed drug of abuse (including but not limited to amphetamines, cannabinoids, barbiturates, cocaine, opiates, benzodiazepines) Participation in a clinical investigation of any drug, biological or other investigational therapy within 30 days prior to dosing Have a history of an allergic reaction to either mifepristone or olanzapine Any clinically significant abnormality on screening laboratory tests QTc Bazzett's ≥ 450 msec Any major medical condition, which in the opinion of the Investigator would place the patient at undue risk. Receiving any prescription or overthecounter medications that could potentially affect appetite or weight History of recent (within 6 months of screening) significant weight fluctuation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>